About 800 reports

  • GASTROINTESTINAL THERAPEUTICS MARKET, GLOBAL, CLINICAL PROGRAM SIZE BY
  • GASTROINTESTINAL THERAPEUTICS MARKET, GLOBAL, CLINICAL TRIAL DURATION BY
  • Clinical Trial
  • World
  • Market Size
  • AstraZeneca PLC
  • Takeda Pharmaceutical Company Limited

The MTD was not reached during this phase of the trial, and the majority of adverse events were mild or moderate gastrointestinal or hematological toxicities.

  • Clinical Trial
  • Forecast
  • Novartis AG
  • Pfizer Inc.
  • Roche Group
  • Clinical Trials by E7 Countries: Proportion of Functional (Non Ulcer) Dyspepsia to Gastrointestinal Clinical Trials
  • Clinical Trials by G7 Countries: Proportion of Functional (Non Ulcer) Dyspepsia to Gastrointestinal Clinical Trials
  • Clinical Trial
  • World
  • Actavis plc
  • Astellas Pharma Inc.
  • Zeria Pharmaceutical Co., Ltd.
  • Proportion of Eosinophilic Esophagitis to Gastrointestinal Clinical Trials, G7 Countries (%), 2015*
  • Clinical Trials by G7 Countries: Proportion of Eosinophilic Esophagitis to Gastrointestinal Clinical Trials
  • Clinical Trial
  • World
  • GlaxoSmithKline plc
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi S.A.

GLP-## agonists have been associated with a common side effect of gastrointestinal disturbances such as nausea and vomiting, which can reduce patient compliance (Prasad-Reddy and Isaacs, 2015).

  • Clinical Trial
  • World
  • AstraZeneca PLC
  • Boehringer Ingelheim GmbH
  • Eli Lilly & Co.

Minor AEs such as stomatitis, headaches, fatigue and gastrointestinal problems such as nausea and vomiting may occur when using Metolate.

  • Clinical Trial
  • World
  • AbbVie Inc.
  • Allergan plc
  • Amgen Inc.
  • Pipeline Landscape Assessment

Gastrointestinal Cancer Research; ##(##): ##-## Mayo Clinic (2014).

  • Clinical Trial
  • World
  • AbbVie Inc.
  • Janssen Biotech, Inc.
  • Johnson & Johnson

When gastrointestinal AEs were reported their intensity was much lower than with oxycodone.

  • Clinical Trial
  • World
  • Amgen Inc.
  • Daiichi Sankyo Company
  • Eli Lilly & Co.

As such, non-selective COX inhibitors typically produce COX-## inhibitory gastrointestinal (GI) side effects, including gastric ulceration, bleeding and perforation.

  • Clinical Trial
  • World
  • Market Size
  • Allergan plc
  • Amgen Inc.
  • Ph ase I
  • Pharmaceutical Industry, Clinical Trial Duration in Phase I by Therapy Area, 2006-

Phase I failure rates ranged broadly from ##% in immunology and ##% in gastrointestinal disorders to ##% in musculoskeletal disorders.

  • Clinical Trial
  • Pharmaceutical
  • Therapy
  • Europe
  • Market Size

AS CF IS A MULTI-SYSTEM DISEASE, EVEN IF THE LUNG TRANSPLANT IS SUCCESSFUL, PANCREATIC, GASTROINTESTINAL AND REPRODUCTIVE PROBLEMS WILL REMAIN.

  • Clinical Trial
  • World
  • Market Size
  • Astellas Pharma Inc.
  • AstraZeneca PLC

As previously outlined, Xenical is a gastrointestinal lipase inhibitor that acts specifically in the lumen of the stomach and small intestine.

  • Clinical Trial
  • World
  • Eli Lilly & Co.
  • Merck & Co., Inc.
  • Novo Nordisk Group

This method avoids the gastrointestinal tract and leads to more rapid effects, compared to orally administered levodopa.

  • Clinical Trial
  • World
  • Biogen Idec Inc.
  • Novartis AG
  • Roche Group

Dietary factors have a substantial influence on the risk of cancers of the gastrointestinal tract.

  • Clinical Trial
  • World
  • Market Size
  • Juno Therapeutics Inc.
  • Merck & Co., Inc.

Gastrointestinal Cancer Research; ##(##): ##-## Hurwitz H, et al. (2004).

  • Cancer
  • Clinical Trial
  • World
  • Market Size
  • Merck & Co., Inc.
  • Clinical Trials by G7 Countries: Proportion of Reflux Esophagitis (Gastroesophageal Reflux Disease) to Gastrointestinal Clinical Trials
  • PROPORTION OF REFLUX ESOPHAGITIS (GASTROESOPHAGEAL REFLUX DISEASE) TO GASTROINTESTINAL CLINICAL TRIALS, E7 COUNTRIES
  • Clinical Trial
  • World
  • AstraZeneca PLC
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited
  • Clinical Trials by E7 Countries: Proportion of Diarrhea to Gastrointestinal Clinical Trials
  • Proportion of Diarrhea to Gastrointestinal Clinical Trials, G7 Countries (%), 2015*
  • Clinical Trial
  • Drug Discovery And Development
  • United States
  • World
  • Furiex Pharmaceuticals, Inc.

GASTROINTESTINAL EVENTS SUCH AS NAUSEA AND DIARRHEA OCCURRED MOST FREQUENTLY.

  • Clinical Trial
  • Asia
  • World
  • Novo Nordisk Group
  • Sanofi S.A.
  • PROPORTION OF ULCERS TO GASTROINTESTINAL CLINICAL TRIALS, G7 COUNTRIES (%), 2015*
  • Clinical Trials by G7 Countries: Proportion of Ulcers to Gastrointestinal Clinical Trials
  • Clinical Trial
  • World
  • AstraZeneca PLC
  • POZEN Inc.
  • Takeda Pharmaceutical Company Limited
  • Clinical Trials by G7 Countries: Proportion of Corrosive Esophagitis (Erosive Esophagitis) to Gastrointestinal Clinical Trials
  • PROPORTION OF CORROSIVE ESOPHAGITIS (EROSIVE ESOPHAGITIS) TO GASTROINTESTINAL CLINICAL TRIALS, G7 COUNTRIES (%), 2015*
  • Clinical Trial
  • Digestive System Disorder
  • World
  • Market Size
  • Takeda Pharmaceutical Company Limited
  • UPPER GASTROINTESTINAL ADENOCARCINOMA
  • KIDNEY DISEASE THERAPEUTICS CLINICAL TRIALS MARKET, GLOBAL, CLINICAL TRIALS BY TEHRAN UNIVERSITY OF MEDICAL SCIENCES,
  • Clinical Trial
  • World
  • AbbVie Inc.
  • Novartis AG
  • OPKO Health, Inc.
  • PROPORTION OF ESOPHAGEAL DISEASES TO GASTROINTESTINAL CLINICAL TRIALS, E7 COUNTRIES (%), 2015*
  • Clinical Trials by G7 Countries: Proportion of Esophageal Diseases to Gastrointestinal Clinical Trials
  • Clinical Trial
  • World
  • AstraZeneca PLC
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited
  • Proportion of Gastric Injury to Gastrointestinal Clinical Trials, G7 Countries (%), 2015*
  • Clinical Trials by G7 Countries: Proportion of Gastric Injury to Gastrointestinal Clinical Trials
  • Clinical Trial
  • Drug Discovery And Development
  • Therapy
  • World
  • NicOx S.A.
  • PROPORTION OF ESOPHAGITIS TO GASTROINTESTINAL CLINICAL TRIALS, G7 COUNTRIES (%), 2015*
  • Clinical Trials by E7 Countries: Proportion of Esophagitis to Gastrointestinal Clinical Trials
  • Clinical Trial
  • World
  • AstraZeneca PLC
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited
  • Clinical Trial
  • World
  • Adverum Biotechnologies, Inc.
  • Alcon, Inc.
  • Allergan plc

It is also in development within the gastrointestinal disease area.

  • Clinical Trial
  • World
  • Market Size
  • Celgene Corporation
  • Novartis AG

Minor AEs such as stomatitis, headaches, fatigue and gastrointestinal problems such as nausea and vomiting may occur when using methotrexate.

  • Clinical Trial
  • Dermatology
  • World
  • Market Size
  • Biologics, Inc.
  • Clinical Trials by G7 Countries: Proportion of Gastric Ulcers to Gastrointestinal Clinical Trials
  • PROPORTION OF GASTRIC ULCERS TO GASTROINTESTINAL CLINICAL TRIALS, G7 COUNTRIES (%), 2015*
  • Clinical Trial
  • Therapy
  • AstraZeneca PLC
  • POZEN Inc.
  • Takeda Pharmaceutical Company Limited
  • PROPORTION OF EMESIS (VOMITING) TO GASTROINTESTINAL CLINICAL TRIALS, G7 COUNTRIES (%), 2015*
  • PROPORTION OF EMESIS (VOMITING) TO GASTROINTESTINAL CLINICAL TRIALS, E7 COUNTRIES (%), 2015*
  • Clinical Trial
  • World
  • Astellas Pharma Inc.
  • Boehringer Ingelheim GmbH
  • Merck & Co., Inc.

In contrast, Tykerb (lapatinib), which also targets HER##, has a very low associated incidence of cardiac AEs and is instead more frequently associated with skin and gastrointestinal events.

  • Clinical Trial
  • World
  • Market Size
  • Bristol-Myers Squibb Company
  • Novartis AG